Menu

Science

Targeting cell states in cancer
Mechanism of Action

Targeting Cancer Cell States

to Block Cancer Growth & Proliferation

In normal, healthy development, cells divide rapidly and proliferate to form the tissues and organs of the human body. Once these cells terminally differentiate, they are committed to a particular cell state and lose the ability to proliferate.

Genetic alterations have the potential to promote tumorigenesis – the process by which normal cells transform into cancer cells. These alterations hijack normal development pathways, pushing cancer cells into an earlier, proliferative cell state – also known as a plastic state. They do this by blocking terminal differentiation, inducing dedifferentiation (reversing a cell’s state to a less specialized and earlier cell state) or inducing transdifferentiation (the conversion of one cell state to another cell state).

The plastic states of cancer cells are associated with the most aggressive, metastatic, and drug-resistant tumors. By targeting the drivers that lock cancer cells in an altered cell state, we can revert the tumor cells back to their normal cell state and inhibit their growth and proliferation.

Our Platform

AURIGIN™ Platform

for Rapid Drug Discovery & Development

We have built a proprietary platform called AURIGIN that we are leveraging for the rapid discovery and development of the next generation of targeted cancer therapies.

AURIGIN is a proprietary platform that integrates our developmental biology expertise with AI Machine Learning algorithms. It includes a database of single cell genomics data that allows it to compare normal cell states to cancer cell states. The power of AURIGIN is its ability to harnesses novel insights into tumor biology and generate validated targets, identify optimized model systems for early program de-risking, and identify biomarkers for effective patient selection.

Our Pipeline

Pipeline Development

for the Next Generation of Targeted Cancer Therapies

We are developing a portfolio that is the direct output of our AURIGIN platform. We have identified a set of priority targets and programs that represent first-in-class or best-in-class opportunities for both solid tumor cancers and hematological malignancies.

  • Includes Breast Cancer, Non-Small Cell Lung Cancer, and Colorectal Cancer
  • Includes Neuroendocrine Prostate Cancer, Small Cell Lung Cancer, Neuroendocrine Tumors, and Neuroblastoma
  • EMT = Epithelial-Mesenchymal Transition

Focused Team.
One purpose.

We have fostered a culture that encourages our team to be curious, to think strategically and creatively, and to push the limits of science. We honor diversity and individuality, and are united by a single commitment to serve the patients and families who need new treatments.

Make an impact.

Search for open positions at Auron Therapeutics.

Join us

Recent News

See All News
February 8, 2024

Auron Selects First Development Candidate for its Portfolio of Next-Generation Targeted Cancer Treatments from its Novel AURIGIN™ Platform

Auron Therapeutics, a biotechnology company focused on developing next-generation targeted therapies by identifying and treating disrupted cell states of cancer, today announced the nomination of its first development candidate, AUTX-703. Using its proprietary AURIGIN platform, Auron identified a key driver of tumor cell plasticity and discovered AUTX-703, a potent, selective, orally bioavailable small molecule degrader of that target. AUTX-703 is being developed for the treatment of patients with small cell lung cancer (SCLC), neuroendocrine prostate cancer (NEPC), and acute myeloid leukemia (AML).

Read more

Heading

Heading

Heading

Heading

Heading
Heading

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Suspendisse varius enim in eros elementum tristique. Duis cursus, mi quis viverra ornare, eros dolor interdum nulla, ut commodo diam libero vitae erat. Aenean faucibus nibh et justo cursus id rutrum lorem imperdiet. Nunc ut sem vitae risus tristique posuere.

This is some text inside of a div block.
This is some text inside of a div block.
This is some text inside of a div block.
This is some text inside of a div block.
This is some text inside of a div block.
This is some text inside of a div block.
This is some text inside of a div block.
This is some text inside of a div block.
This is some text inside of a div block.
This is some text inside of a div block.
This is some text inside of a div block.
This is some text inside of a div block.
This is some text inside of a div block.
This is some text inside of a div block.
This is some text inside of a div block.
This is some text inside of a div block.
This is some text inside of a div block.
aspekta 200
aspekta 700
barlow 200